Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilofexor (Primary) ; Firsocostat (Primary) ; Selonsertib (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ATLAS
  • Sponsors Gilead Sciences

Most Recent Events

  • 14 Nov 2023 Results assessing Increased Cardiovascular and Kidney Disease Risk in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
  • 08 Nov 2022 Results (n=198) assessing the changes of plasma proteome markersin patients with NASH via SomaScan, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
  • 01 Nov 2022 According to a Gilead Sciences media release, data from the trial will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top